Patient-derived induced pluripotent stem cells for models of cancer and cancer stem cell research

Chao, Hsiao-Mei; Chern, Edward

doi:10.1016/j.jfma.2018.06.013

Cited by 30 publications

(24 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In cancer, as the CRC cells, they can be widely used to study several tumors phenotypes in a patient-specific model. 152,153 Patient-derived tumor xenografts, which are generated by transplanting fresh tumor tissues from patients into immunodeficient mice, can retain tumor heterogeneity and genomic stability, as well as reproduce complex cancer-stroma and cancer-matrix interactions, better predicting drug responses. 154,155 However, their application in medicine can be limited, due to its high cost and long processing time.…”

Section: Future Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

An overview of neuroblastoma cell lineage phenotypes andin vitromodels

Cogo

Nascimento

Pinhatti

et al. 2020

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

This review was conducted to present the main neuroblastoma (NB) clinical characteristics and the most common genetic alterations present in these pediatric tumors, highlighting their impact in tumor cell aggressiveness behavior, including metastatic development and treatment resistance, and patients’ prognosis. The distinct three NB cell lineage phenotypes, S-type, N-type, and I-type, which are characterized by unique cell surface markers and gene expression patterns, are also reviewed. Finally, an overview of the most used NB cell lines currently available for in vitro studies and their unique cellular and molecular characteristics, which should be taken into account for the selection of the most appropriate model for NB pre-clinical studies, is presented. These valuable models can be complemented by the generation of NB reprogrammed tumor cells or organoids, derived directly from patients’ tumor specimens, in the direction toward personalized medicine. Impact statement This review provides an update on the mostly used cell line in vitro models for neuroblastoma (NB), a heterogeneous disease with high metastatic potential and resistance to treatment. The genetic and phenotypic profiles of the most used NB cell lines in the last 10 years are presented, considering the molecular markers that are involved in the distinct NB tumor phenotypes, including distinct core regulatory circuitries and non-coding RNAs. This gathered information can assist in the selection of the most appropriate NB in vitro model, based on the specific goals and objectives of each study.

show abstract

Section: Future Perspectivesmentioning

confidence: 99%

“…In cancer, as the CRC cells, they can be widely used to study several tumors phenotypes in a patient-specific model. 152,153…”

Section: Future Perspectivesmentioning

confidence: 99%

An overview of neuroblastoma cell lineage phenotypes andin vitromodels

Cogo

Nascimento

Pinhatti

et al. 2020

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

show abstract

“…Moreover, iPS cells derived from cancer cells (cancer-iPS cells) can be a novel strategy for studying cancer. Primary cancer cells have been reprogrammed into iPS cells or at least to a pluripotent state, allowing the study and elucidation of some of the molecular mechanisms associated with cancer progression [58].…”

Section: Disease Differentiated Cell Type Referencementioning

confidence: 99%

Induced Pluripotent Stem Cells: Hope in the Treatment of Diseases, including Muscular Dystrophies

Beghini

Horita

Cascabulho

et al. 2020

IJMS

View full text Add to dashboard Cite

Induced pluripotent stem (iPS) cells are laboratory-produced cells that combine the biological advantages of somatic adult and stem cells for cell-based therapy. The reprogramming of cells, such as fibroblasts, to an embryonic stem cell-like state is done by the ectopic expression of transcription factors responsible for generating embryonic stem cell properties. These primary factors are octamer-binding transcription factor 4 (Oct3/4), sex-determining region Y-box 2 (Sox2), Krüppel-like factor 4 (Klf4), and the proto-oncogene protein homolog of avian myelocytomatosis (c-Myc). The somatic cells can be easily obtained from the patient who will be subjected to cellular therapy and be reprogrammed to acquire the necessary high plasticity of embryonic stem cells. These cells have no ethical limitations involved, as in the case of embryonic stem cells, and display minimal immunological rejection risks after transplant. Currently, several clinical trials are in progress, most of them in phase I or II. Still, some inherent risks, such as chromosomal instability, insertional tumors, and teratoma formation, must be overcome to reach full clinical translation. However, with the clinical trials and extensive basic research studying the biology of these cells, a promising future for human cell-based therapies using iPS cells seems to be increasingly clear and close.

show abstract

“…Transcription factor-mediated reprogramming can be further directed, by a variety of differentiation-associated factors, to form functional cells of diverse lineages [64]. Although such reprogramming approach is feasible and ethically-acceptable to re-activate the post-epigenetic state of cancer cells back into a benign pluripotent state [65], the efficiency and safety of cancer cell reprogramming mediated by transcription factors remain a challenging task to be solved before it becomes a promising therapy for cancer [29].…”

Section: Reprogramming Cancer Cells To Benign Cellsmentioning

confidence: 99%

Cancer cell reprogramming: a promising therapy converting malignancy to benignity

Gong

Yan

Zhang

et al. 2019

Cancer Communications

View full text Add to dashboard Cite

In the past decade, remarkable progress has been made in reprogramming terminally differentiated somatic cells and cancer cells into induced pluripotent cells and cancer cells with benign phenotypes. Recent studies have explored various approaches to induce reprogramming from one cell type to another, including lineage-specific transcription factors-, combinatorial small molecules-, microRNAs- and embryonic microenvironment-derived exosome-mediated reprogramming. These reprogramming approaches have been proven to be technically feasible and versatile to enable re-activation of sequestered epigenetic regions, thus driving fate decisions of differentiated cells. One of the significant utilities of cancer cell reprogramming is the therapeutic potential of retrieving normal cell functions from various malignancies. However, there are several major obstacles to overcome in cancer cell reprogramming before clinical translation, including characterization of reprogramming mechanisms, improvement of reprogramming efficiency and safety, and development of delivery methods. Recently, several insights in reprogramming mechanism have been proposed, and determining progress has been achieved to promote reprogramming efficiency and feasibility, allowing it to emerge as a promising therapy against cancer in the near future. This review aims to discuss recent applications in cancer cell reprogramming, with a focus on the clinical significance and limitations of different reprogramming approaches, while summarizing vital roles played by transcription factors, small molecules, microRNAs and exosomes during the reprogramming process.

show abstract

Patient-derived induced pluripotent stem cells for models of cancer and cancer stem cell research

Cited by 30 publications

References 96 publications

An overview of neuroblastoma cell lineage phenotypes andin vitromodels

An overview of neuroblastoma cell lineage phenotypes andin vitromodels

Induced Pluripotent Stem Cells: Hope in the Treatment of Diseases, including Muscular Dystrophies

Cancer cell reprogramming: a promising therapy converting malignancy to benignity

Contact Info

Product

Resources

About